Management Board of MorphoSys AG
Transcription
Management Board of MorphoSys AG
12 THE COMPANY Management Board of MorphoSys AG Management Board of MorphoSys AG DR. SIMON MORONE Y Chief Executive Officer THE COMPANY Management Board of MorphoSys AG » Excellent progress over the last year means that today our pipeline is broader and more mature than ever before. The first therapeutic antibodies are nearing market approval, bringing us closer to a product-based revenue stream. Meanwhile, our proprietary develop ment portfolio is expanding and the two most advanced programs are approaching decisive stages of clinical development. Across our entire pipeline, we see many pro grams with outstanding therapeu tic potential, to the benefit of all of our stakeholders, not least the patients who they will help. « JENS HOL S T EIN Finanzvorstand Letter to the Shareholders 13 12 THE COMPANY Management Board of MorphoSys AG Management » With Board financial resources of close of MorphoSys to EUR AG 300 million at year-end 2015, MorphoSys continues to operate from a position of strength. Our solid financial base has been the foundation for MorphoSys’s successful develop ment over the years, allowing us to continue making targeted investments and grow the Com pany’s value without losing sight of our prudent and efficient use of resources. « DR. SIMON MORONE Y Vorstandsvorsitzender THE COMPANY Management Board of MorphoSys AG JENS HOL S T EIN Chief Financial Officer 13 14 THE COMPANY Management Board of MorphoSys AG DR. MARL IE S SPROL L Chief Scientific Officer THE COMPANY Management Board of MorphoSys AG » During 2015, our product pipeline became broader and more mature than ever before. Our partnered programs are on the cusp of reap ing the first rewards of our long time efforts. In 2016, Novartis’s bimagrumab and Janssen’s gusel kumab will be the first HuCAL anti bodies to deliver phase 3 data, and we may see the first MorphoSys antibody reach the market before year-end – another exciting year is lying ahead. « DR. ARND T S C HO T T EL IUS Chief Development Officer 15 14 THE COMPANY Management Board of MorphoSys AG » In 2015 we generated encouraging clinical data with our proprietary cancer agents. We are now expand ing these programs and moving them, step-by-step, towards ap proval and commercial viability. At the center of this campaign will be the start of three combination studies with our most advanced antibody MOR208 in DLBCL and CLL in 2016, one of which is expected to progress directly into a pivotal study next year, marking yet an other major milestone in the history of MorphoSys. « DR. MARL IE S SPROL L Chief Scientific Officer THE COMPANY Management Board of MorphoSys AG DR. ARND T S C HO T T EL IUS Chief Development Officer 15